{"version":"1.0","provider_name":"Indonesia Tribune","provider_url":"https:\/\/indonesiatribune.com","author_name":"admin","author_url":"https:\/\/indonesiatribune.com\/author\/admin\/","title":"Ambulero\u2019s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease - Indonesia Tribune","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"VGfoMiXepF\"><a href=\"https:\/\/indonesiatribune.com\/ambuleros-gene-therapy-candidate-amb-301-granted-us-orphan-drug-designation-for-treatment-of-severe-vascular-disease\/\">Ambulero\u2019s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/indonesiatribune.com\/ambuleros-gene-therapy-candidate-amb-301-granted-us-orphan-drug-designation-for-treatment-of-severe-vascular-disease\/embed\/#?secret=VGfoMiXepF\" width=\"600\" height=\"338\" title=\"&#8220;Ambulero\u2019s Gene Therapy Candidate AMB-301 Granted US Orphan Drug Designation For Treatment of Severe Vascular Disease&#8221; &#8212; Indonesia Tribune\" data-secret=\"VGfoMiXepF\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Ambulero Inc Receives Key FDA Recognition For Novel Gene Therapy To Treat Buerger\u2019s Disease (Thromboangiitis Obliterans) MIAMI, Oct. 19, 2021 (GLOBE NEWSWIRE) \u2014 Ambulero Inc., a biotechnology company (\u201cAmbulero\u201d or the \u201cCompany\u201d) developing new cell and gene therapy treatments for patients suffering from severe vascular disease, today announced that the U.S. FDA\u2019s Office For Orphan [\u2026]"}